ATS View
한국어

Cell Biotech KRX:049960KOSDAQ

쎌바이오텍 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked29since Sep 11

In Q2 2026, Cell Biotech reported revenue of ₩15.8bn, up 32.8% year on year, and operating profit of ₩1.6bn. Cell Biotech (쎌바이오텍) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 11 articles.

Filing signals Revenue +30% Revenue & profit growth Screener

Cell Biotech quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩15.8bn+32.8%₩1.6bn
margin 10.4%		₩3.6bn
Q1 2026₩14.6bn+30.0%₩3.2bn
margin 21.8%		₩5.4bn
Q4 2025 derived₩14.6bn+20.4%₩3.1bn
margin 20.9%		₩4.4bn
Q3 2025₩15.4bn+26.3%₩2.2bn
margin 14.4%		₩3.4bn
Q2 2025₩11.9bn-5.2%₩1.3bn
margin 10.8%		₩213m
Q1 2025₩11.2bn-13.9%₩1.4bn
margin 12.1%		₩2.1bn
Q4 2024 derived₩12.2bn-18.1%₩1.1bn
margin 9.3%		₩6.9bn
Q3 2024₩12.2bn-11.0%₩2.1bn
margin 17.2%		₩969m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Cell Biotech top stories 2 weeks, by number of outlets

  1. 1
    쎌바이오텍 듀오락, CBT 유산균 만성콩팥병 개선 기전 규명
    4 outlets · 4 articlesFirst report Oct 20 08:36 뉴스핌
  2. 2
    쎌바이오텍, 장 다스려 콩팥을 살린다…‘K유산균’이 밝혀낸 장-신장 축의 기적
    1 outlets · 2 articlesFirst report Oct 20 15:17 이데일리
  3. 3
    ‘장-신장 축’ 규명한 K-유산균…쎌바이오텍, 만성콩팥병 독소 억제 기전 입증
    1 outlets · 1 articlesFirst report Oct 20 10:10 식품음료신문
  4. 4
    쎌바이오텍, CBT 유산균 신장손상 전임상 연구 발표
    1 outlets · 1 articlesFirst report Oct 20 12:49 메디포뉴스
  5. 5
    쎌바이오텍, 유산균의 만성콩팥병 개선 기전 연구…요독소 감소 확인
    1 outlets · 1 articlesFirst report Oct 20 10:15 뉴스1
  6. 6
    쎌바이오텍 "만성콩팥병 후속연구 학술지 게재"
    1 outlets · 1 articlesFirst report Oct 20 17:36 뉴시스경제

Latest Cell Biotech news Korean headlines